Clinical trials: Middle Rectal Cancer
Rectal Cancer, Retention, Urinary
Incidence of Acute Urine Retention: Randomized Clinical Trial Comparing Early, Mid or Late Urinary Catheter Removal in Patients With Rectal Resection
DESIGN: Randomized, open-label and parallel clinical trial, assigned to early, mid, or late withdrawal of urinary catheter with a 1: 1: 1 allocation ratio.
- Conditions
- Rectal Cancer, Retention, Urinary, Urinary Tract Infections, Surgical Site Infection
- Trial name
- RAOREC (NCT04751149)
- Testing
- Removal of Urinary Catheter
- Where
- Spain
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Hospital Donostia
Localized Advanced Rectal Adenocarcinoma
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer
The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by total mesorectal excision.
- Trial name
- NCT06931808
- Testing
- Sintilimab plus Chemotherapy, Intestinal microbiota capsules, Standard Long Course Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Locally Advanced Rectal Cancer
Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer
This is a multicenter, prospective, randomized controlled study to evaluate the effectiveness and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and PCSK9 inhibitor in the treatment of patients with pMMR/MSS…
- Trial name
- NCT06304987
- Testing
- Long-course chemoradiation and PD-1 inhibitor, with PCSK9 inhibitor, Long-course chemoradiation and PD-1 inhibitor, without PCSK9 inhibitor
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Beijing Friendship Hospital
Rectal Cancer
Rectal Cancer Response Hybrid Imaging Assessement
Rectal cancer represents 14,000 new cases a year in France. At diagnosis, 70% of patients have a locally advanced tumors T3-T4 and / or N + evaluated mainly by rectal MRI.
- Trial name
- RECARHIA (NCT04036643)
- Testing
- PET-MRI
- Where
- France
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diverting Ileostomy, Middle and Low Rectal Cancer
Diverting Ileostomy and Anal Functional Outcomes After Anus Preservation Surgery
Analyze the occurrence of complications, rectal function and quality of life after anus-preserving surgery for middle and low rectal cancer, so as to evaluate the role of protective ileostomy.
- Conditions
- Diverting Ileostomy, Middle and Low Rectal Cancer, Functional Outcome, Stoma Complications
- Trial name
- NCT04776421
- Testing
- Diverting ileostomy
- Volunteers
- 300 people
- Sponsor
- The First Hospital of Jilin University
Rectal Cancer
A Trial to Assess Robot-assisted Surgery and Laparoscopy-assisted Surgery in Patients With Mid or Low Rectal Cancer
This study sets up the final study end point and three detailed goals as the following. The main objective of study: This trial is done to assess the safety and benefit of robotic resection compared with conventional…
- Trial name
- COLRAR (NCT01423214)
- Testing
- robot-assisted surgery, Laparoscopic surgery
- Where
- 3 sites in South Korea
- Volunteers
- 540 people
- Sponsor
- Kyungpook National University Hospital
Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial aims to assessing the efficacy and safety of neoadjuvant chemoradiation plus Tislelizumab (PD-1 inhibitor) with or without Probio-M9 and subsequent TME surgery, by…
- Conditions
- Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy, Immunotherapy, Probio-M9
- Trial name
- NCRIT-PM9 (NCT07458529)
- Testing
- CRT+PD-1 inhibitor+Probio-M9
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Seventh Medical Center of PLA General Hospital
Rectal Carcinoma, Surgery
COLOR III Trial: Transanal vs Laparoscopic TME
Background Surgery for mid and low rectal cancer is associated with relative high rates of incomplete mesorectal excisions and high rates of circumferential resection margin (CRM) involvement resulting in significant number of…
- Trial name
- COLORIII (NCT02736942)
- Testing
- Laparoscopic TME, TaTME
- Where
- Netherlands
- Volunteers
- 1,104 people
- Sponsor
- Amsterdam UMC, location VUmc
Colorectal Cancer
Comparison of Two Types of Surgery in Treating Patients With Rectal Cancer
RATIONALE: Surgery to remove the tumor may be an effective treatment for rectal cancer. It is not yet known whether one type of surgery is more effective than another for rectal cancer.
- Trial name
- NCT00007930
- Testing
- conventional surgery, laparoscopic surgery
- Where
- 3 sites in China, Singapore
- Volunteers
- 800 people
- Sponsor
- National Medical Research Council (NMRC), Singapore
Rectal Cancer, Metastasis
Study of Radiation Therapy in Combination With Xeloda, for Initially Metastatic, Low and Middle Rectal Cancer
In initially metastatic rectal carcinoma, a neo-adjuvant multi-drug chemotherapy is usually performed, followed by a pelvic chemoradiation.
- Conditions
- Rectal Cancer, Metastasis, Radiotherapy
- Trial name
- DESIR (NCT03634202)
- Testing
- IMRT + oral chemotherapy
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Institut Cancerologie de l'Ouest
Colorectal Cancer, Wound Infection
Comparing PP and PVDF Meshes in Midline Laparotomy Closure for High-risk Colorectal Surgery. Impact on Incisional Hernia and Surgical Wound Infection.
In the latest guidelines for abdominal wall closure in emergency surgery published in the World Journal of Emergency Surgery (WJES) in 2023, no specific recommendations are made in this regard.
- Conditions
- Colorectal Cancer, Wound Infection, Hernia Incisional
- Trial name
- PROFIMESH (NCT06220045)
- Testing
- Polyvinylidene fluoride mesh, Prophylactic polypropylene mesh
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Rectal Cancer
Pelvic Drain After Rectal Resection for Mid-low Rectal Cancer
This RCT aims at assessing the effects of a pelvic drain after total mesorectal excision for mid-low rectal cancer on the rates of pelvic sepsis and anastomotic leaks.
- Trial name
- GECO1 (NCT04573621)
- Testing
- Pelvic drain, No pelvic drain is placed
- Where
- Spain
- Volunteers
- 518 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Rectal Cancer, Advanced Cancer
Complete Versus Partial Preservation of Denonvilliers' Fascia on Urogenital Function in Locally Advanced Rectal Cancer
Total mesorectal resection (TME) is the standard surgical method for locally advanced rectal cancer, which significantly reduces the local recurrence rate. However, the incidence of urogenital dysfunction is higher.
- Trial name
- NCT04672603
- Testing
- Complete Preservation of Denonvilliers' Fascia
- Where
- China
- Volunteers
- 214 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
This randomized phase I/II trial studies the side effects, best way to give, and best dose of erlotinib and bevacizumab when given with cetuximab and how well giving erlotinib and cetuximab together with or without bevacizumab…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Colon Cancer
- Trial name
- NCT00101348
- Testing
- erlotinib hydrochloride, cetuximab, bevacizumab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Tislelizumab, Locally Advanced Rectal Cancer
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
There have been many high-quality research publications, including the TNT model of short-term radiotherapy combined with consolidation chemotherapy, and the TNT model of three-drug combination with neoadjuvant chemotherapy with…
- Conditions
- Tislelizumab, Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, PD-1
- Trial name
- STARS-RC03 (NCT04906044)
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- The First Hospital of Jilin University
Rectal Cancer
Transanal Total Mesorectal Excision Versus Robotic Total Mesorectal Excision
Background: Laparoscopic total mesorectal excision (TME) for rectal cancer is technically challenging because of the confined space within the pelvis.
- Trial name
- TaRo (NCT04091620)
- Testing
- Transanal Total Mesorectal Excision, Robotic Total Mesorectal Excision
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Chinese University of Hong Kong
Rectal Cancer
Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery
Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment, will receive a preoperative…
- Trial name
- PIER (NCT03000374)
- Testing
- Panitumumab, 5Fluorouracil, Oxaliplatin
- Where
- 11 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Rectal Cancer
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer
The goal of this clinical trial is to learn if neoadjuvant Fruquintinib and Tislelizumab combined with mCapeOX works to treat mid-high pMMR/MSS locally advanced rectal cancer patients compared with CapeOX.
- Trial name
- PKUCH-R09 (NCT06443671)
- Testing
- CapeOX, Fruquintinib and Tislelizumab combined with mCapeOX
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Peking University Cancer Hospital & Institute